SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2019; 54(2):

Published online June 30, 2019

https://doi.org/10.5045/br.2019.54.2.151

© The Korean Society of Hematology

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia

Da Jung Kim1, Seri Jeong2, Seom Gim Kong3, Ho Sup Lee1

Author Info. +

1Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, 2Department of Laboratory Medicine and 3Pediatrics, Kosin University College of Medicine, Busan, Korea

Correspondence to : Ho Sup Lee
Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea
E-mail: hs52silver@gmail.com

Received: March 8, 2018; Revised: January 16, 2019; Accepted: January 22, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

FIGURES

Go to
Fig. 1.

Computed tomography scan of the chest. Lung setting view image showed diffuse subtle ground glass opacities in the hemithoraces, and atypical pneumonia such as viral infection, pneumocystis pneumonia, miliary TB, or drug-induced pneumonitis was suspected.


Fig. 2.

Changes in BCR-ABL real-time quantitative PCR (RQ-PCR) results according to antituberculosis medication and CML medication. After antituberculosis medication, BCR-ABL RQ-PCR results remained relatively stable and showed a major molecular response.


REFERENCES

Go to
  1. Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights 2016;10:55-68.
    Pubmed
  2. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 2009;33:670-672.
    Pubmed
  3. Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009;90:383-387.
    Pubmed
  4. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976-980.
    Pubmed
  5. García-Muñoz R, Galar A, Moreno C, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48:2461-2464.
    Pubmed
  6. Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med 2009;169:312-313.
    Pubmed
  7. Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-2479.
    Pubmed
  8. Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008;12:2107-2118.
    Pubmed
  9. Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297-1308.
    Pubmed
  10. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 2013;122:227-238.
    Pubmed
  11. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
    Pubmed

Article

Letter to the Editor

Blood Res 2019; 54(2): 151-153

Published online June 30, 2019 https://doi.org/10.5045/br.2019.54.2.151

Copyright © The Korean Society of Hematology.

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia

Da Jung Kim1, Seri Jeong2, Seom Gim Kong3, Ho Sup Lee1

1Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, 2Department of Laboratory Medicine and 3Pediatrics, Kosin University College of Medicine, Busan, Korea

Correspondence to:Ho Sup Lee
Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea
E-mail: hs52silver@gmail.com

Received: March 8, 2018; Revised: January 16, 2019; Accepted: January 22, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Fig 1.

    Download
    Figure 1.

    Computed tomography scan of the chest. Lung setting view image showed diffuse subtle ground glass opacities in the hemithoraces, and atypical pneumonia such as viral infection, pneumocystis pneumonia, miliary TB, or drug-induced pneumonitis was suspected.

    Blood Research 2019; 54: 151-153https://doi.org/10.5045/br.2019.54.2.151

    Fig 2.

    Download
    Figure 2.

    Changes in BCR-ABL real-time quantitative PCR (RQ-PCR) results according to antituberculosis medication and CML medication. After antituberculosis medication, BCR-ABL RQ-PCR results remained relatively stable and showed a major molecular response.

    Blood Research 2019; 54: 151-153https://doi.org/10.5045/br.2019.54.2.151

    References

    1. Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights 2016;10:55-68.
      Pubmed
    2. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 2009;33:670-672.
      Pubmed
    3. Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009;90:383-387.
      Pubmed
    4. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976-980.
      Pubmed
    5. García-Muñoz R, Galar A, Moreno C, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48:2461-2464.
      Pubmed
    6. Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med 2009;169:312-313.
      Pubmed
    7. Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-2479.
      Pubmed
    8. Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008;12:2107-2118.
      Pubmed
    9. Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297-1308.
      Pubmed
    10. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 2013;122:227-238.
      Pubmed
    11. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
      Pubmed
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download